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INTRODUCTION 
During the first 100 years after Paul Ehrlich 
discovered them, mast cells were believed to be a 
component of connective tissue that was derived 
from undifferentiated mesenchymal cells.1 
However, Kitamura and co-workers 2 demonstrated 
that mast cells (MCs) arise from multipotent 
hematopoietic progenitors in bone marrow. These 
cells took their name from the Greek word 
mastzellen, meaning well-fed as Paul observed the 
granular nature of the cells.3 
MCs are usually perivascular. They are 
generally noted to be particularly abundant in 
tissues that are exposed to the environment.4,5 
Committed MC progenitors are rare in bone 
marrow suggesting they are rapidly released into 
the blood where they circulate and move out into 
the peripheral tissues. This migration is controlled 
in a tissue specific manner. Basal trafficking to the 
intestine or the lung requires expression of α4β7 
integrin and the chemokine receptor CXCR2 by the 
MC progenitors and expression of VCAM-1 in the 
intestinal and pulmonary endothelium.6 In humans, 
MCs have been described to reach densities of up to 
500 to 4,000 per mm3 in the lungs, 7,000 to 12,000 
per mm3 in skin and 20,000 per mm3 in the 
gastrointestinal tract.7 These densities have been 
noted to increase in the skin of humans that is not 
covered by clothing, suggesting that regions that 
experience continual environmental exposure 
respond by either recruiting more MCs or inducing 
their local proliferation.8  
Since their discovery in 1878, MCs have 
primarily been regarded as effector cells promoting 
harmful IgE mediated allergic reactions following 
secondary exposure to allergens.9 However, in the 
last decade they were being increasingly recognized 
for their key role in pathogen recognition, and in 
initiating primary protective innate and adaptive 
immune responses.9,10 To function as immune 
surveillance cells, MCs must be able to interact 
with incoming pathogens. MC activation usually 
occurs through at least 3 mechanisms of pathogen 
recognition: (i) direct binding of pathogens or their 
components by pathogen associated molecular 
pattern (PAMP) receptors located on the MC 
surface; (ii) binding of opsonized bacteria or their 
products by complement receptors or 
immunoglobulin receptors, or (iii) recognition of 
endogenous peptides produced by infected or 
injured host cells. One class of PAMP receptors are 
the Toll like receptors (TLRs).11 Each TLR binds a 
specific component of different pathogens. Human 
MCs have been shown to express TLR-1,-2,-3,-4,-
5,-6,-7 and -9 under certain conditions.12,13 
 
Mast cell and initiation of allergic sensitization 
In atopic patients, allergens are recognized, 
processed and presented by antigen presenting cells 
such as dendiritic cells, in association with MHC II 
and co-stimulatory molecules, to naïve T cells. 
Naïve T cells that recognize the allergen as foreign 
then differentiate into Th2 type T cells which 
produce cytokines that enhance allergen specific 
IgE synthesis by B cells. This primary immune 
response is termed allergen sensitization and has 
been previously thought to occur without 
involvement of mast cells.14 (figure 1). 
However, new evidence suggested that MCs 
might coordinate and drive a Th2 immune response 
to innocuous agents particularly when these 
innocuous agents are encountered in the setting of 
endotoxin exposure. Endotoxins are common 
contaminants in the environment and can act on 
MCs via TLRs.  When an individual encounters 
allergen and low doses of endotoxin in the 
environment together, MC activation through TLR 
signaling may lead to MC secretion of cytokines 
such as TNFα into the local environment.  TNFα 
induces the expression of E–selectin on vascular 
endothelial cells which induce dendiritic cell 
chemotaxis.  Dendiritic cells then migrate to the 
lymph node leading to an inappropriate Th2 
immune response to the innocent allergen in a 
“bystander phenomenon” resulting in B cell 
production of a specific IgE with subsequent 
induction of MC FcεRI to this specific IgE and so 
allergen sensitization.15,16,17  
In a mouse model of asthma, intranasal 
administration of low dose Lipopolysaccharide 
(LPS) and antigen resulted in markedly enhanced 
eosinophil accumulation in the lung upon antigen 
re-challenge as compared to mice that were 




dose LPS and antigen.15,17 In addition, serum 
antibodies in mice treated with low dose LPS and 
antigen showed a Th2 pattern (high IgE and IgG1) 
as opposed to those from mice treated with high 
dose LPS and antigen (high IgG2a-Th1 pattern).15 
When this experiment was performed in MC 
deficient mice, eosinophilic infiltration was 
markedly low and was restored when MC deficient 
mice underwent MC repletion prior to exposure to 
LPS and allergen thereby indicating that MCs were 
important in the process of allergen 
sensitization.15,17 
Once allergen sensitization has occurred, MCs 
expressing allergen specific IgE may amplify the 
allergic response by acting as antigen presenting 
cells to further drive allergen specific Th2 
proliferation.14  
Mast cell and early phase allergic reaction 
Mast cells and basophils are the two major cell 
populations that express high affinity FcεRI and the 
number of surface FcεRI is up-regulated by 
increased concentrations of immunoglobulin. 
Aggregation of only a small fraction of mast cells’ 
FcεR1 is sufficient to trigger mast cell activation 
and mediator release.18 This FcεRI-dependent mast 
cell activation response results in rapid release (in 
minutes) of preformed cytoplasmic granule-
associated mediators (such as histamine, heparin, 
tryptase and other proteoglycans, proteases as MC 
chymases) and certain cytokines (TNFα, VEGF and 
other ILs) together with the secretion of de novo-
synthesized lipid mediators (including cysteinyl 





1. MCs degranulate when allergen binds to IgE on the MC surface. 2. MCs play a key role 
in allergen sensitization when allergen exposure occurs in the presence of bacterial 
byproducts. 3. Allergen and bacterial products act synergistically to increase MC granule 
release. 
Quoted from (Hofman and Abraham, 2010)14. 
 
Figure 1. Mast cell roles in allergic diseases. 
 
Mast cell and late phase allergic reaction 
Late phase reaction is mainly produced by cells 
of the immune system. Mast cells produce, with a 
prolonged kinetics, many cytokines, chemokines 
and growth factor.17,18,19 Among these cytokines are  
IL-1, IL-3, IL-4, IL-5, IL-13, TNF-a, and GM-CSF, 
and chemokines; including IL-8, eotaxin, regulated 
upon activation normal T cell expressed and 
secreted (RANTES), and monocyte chemotactic 
protein-1(MCP-1)21. IL-2 usually serves as an 
important eosinophil chemoattractant. IL-3, IL-5, 
and GM-CSF delay the apoptosis of eosinophils for 
a minimum of 12–14 days, whereas in their 
absence, the life-span of these cells does not exceed 
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48 hours.22,23 They also cause eosinophils to express 
large numbers of receptors for cytokines, 
immunoglobulins, and complement22. IL-5 induces 
eosinophil differentiation in the bone marrow and 
also stimulates eosinophil precursors to synthesize 
granule proteins.24 In addition to selective 
differentiation of eosinophils, IL-5 is responsible 
for their mobilization and release from bone 
marrow into the bloodstream.22,25,26 IL4 up-
regulates FcεR1 and allows eosinophil 
recruitment.27 RANTES is a strong chemoattractant 
and induce histamine release from basophils. MPC 
recruits monocytes-macrophage lineage cells. 21  
Recent studies have identified a “Th2 cell- mast 
cell- eosinophil axis”. Stem cell factor (SCF) 
produced from eosinophils allows MC proliferation 
and activation. In return, MCs regulate SCF release. 
Th2 cytokine- stimulated MCs express more 
inflammatory mediators that can activate 
eosinophils.28,29 
Many studies tried to elicit the role of MC in 
allergy. Mouse models of asthma showed that MCs 
and MC derived TNFα contribute to both airway 
hyperactivity and inflammation.30 LTB4 produced 
on MC activation induces airway inflammation by 
recruiting effector CD8 and CD4 T cells.31 MCs 
also contribute to a model of Th17 cell-dependent 
neutrophils-associated lung inflammation in 
ovalbumin (OVA), OVA-specific T-cell receptor 
transgenic mice.30 
In a rodent model of atopic dermatitis (AD), 
MC degranulation was correlated with the severity 
of AD.32 In a study comparing the serum levels of 
soluble growth factor for MCs; SCF and its receptor 
KIT in AD patients versus patients with psoriasis, 
the level of SCF and soluble KIT were elevated 
only in AD patients especially those with severe 
disease. These studies indicated that MCs might 
serve as a marker of severity in AD.33 There has 
been a number of reports on the association of AD 
with polymorphism of mast cell-related genes as 
polymorphism in the chain of high affinity of IgE 
receptor and genetic variants of MC chymase.34,35 
 
Mast cell and exacerbation of the allergic 
reaction 
Infection exacerbates allergic diseases particularly, 
asthma and atopic dermatitis through different 
mechanisms. Multiple studies detected circulating 
IgE antibodies to staphylococcal superantigens, 
including enterotoxin A (SEA), staphylococcal 
enterotoxin B (SEB), and toxic shock syndrome 
toxin-1, in almost 30- 50% of patients with atopic 
dermatitis (AD).36,37 In chronic rhinosinusitis, S. 
aureus enterotoxin B shifts the cytokine pattern 
toward Th2 and induces polyclonal IgE production, 
which might contribute to severe inflammation via 
the activation of the mast cells.38 In a recent study 
on 73 patients with moderate to severe AD, the 
investigators found a high prevalence of IgE 
antibodies to Malassezia furfur and Alternaria 
alternara.39  
Toll-like receptors (TLRs) on MCs play an 
important role in allergy exacerbation.  Activation 
of TLR signaling in addition to FcεRI signaling in 
the setting of infection and allergen exposure causes 
enhanced MC activation and worsening of 
established allergic disease. Peptidoglycan (PGN) 
from S. aureus stimulated mast cells in a TLR2-
dependent manner to produce TNFα, IL-4, IL-5, IL-
6, and IL-13. The intradermal injection of PGN in a 
mouse model induced skin vasodilatation and 
inflammation through the TLR2-dependent 
activation of MCs.40 In bronchial asthma, dual 
activation of TLR4 or TLR2 on the MC surface by 
lipopolysaccharides (LPS) of gram negative 
bacteria or PGN of Gram positive bacteria, in 
association with FcεRI stimulation by an allergen 
acted synergistically to increase cytokine 
production by MCs.  In the setting of dual TLR-
FcεRI signaling, MCs produced augmented 
amounts of IL-6, IL-13, and TNFα.41 IL-6 and 
TNFα have been shown to recruit neutrophils into 
the site of MC activation while IL-13 promoted a 
Th2 response in T cells and initiated IgE class 
switching, all of which served to exacerbate allergic 
asthma. Some viruses, such as Respiratory 
Syncytial Virus (RSV), a known asthma trigger, 
contain proteins such as HsP60 and F-protein which 
can activate TLR4.42 In theory, dual activation of 
TLR 4 and FcεRI on MCs in the setting of 
simultaneous allergen exposure and RSV infection 
could lead to increased cytokine production and 
TNFα release by MCs thereby worsening asthma 
symptoms.14 
MCs can also amplify the allergic response in 
the uninfected host through acting as antigen 
presenting cells in the setting of allergen re-
exposure after sensitization. MCs have the ability to 
phagocytose antigens that bind to surface receptors 
and to process and display them on the MC surface 
in the setting of MHC I or even, perhaps, MHC II 
under certain conditions. MCs bearing MHC 
allergen complexes could then stimulate CD 8+ or 
CD 4+ effector T cells located in peripheral sites 
such as the skin or lungs where MCs are naturally 
found leading to expansion and proliferation of the 
particular allergen specific T cell line. Increased 
numbers of allergen specific CD8 T+ cells and CD 
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 58
4 T+ cells contributed to exacerbations of allergic 
diseases especially asthma.43 
 
Mast cells and tissue remodeling 
There is a controversy whether MCs induce or 
prevent tissue remodeling in chronic inflammation. 
In a mouse model of asthma, MCs increased the 
numbers of mucus-producing goblet cells in the 
airway epithelium and increased collagen 
deposition.44 In another model, mice lacking the 
MC chymase exhibited more substantial increase in 
airway reactivity to metacholine, more airway 
inflammation and thickening of bronchial smooth 
muscle than the wild mice strain.45 This might 
indicate that at least one product of the mast cell 
might help to limit the pathology associated with 
allergic inflammation.9 In AD model, MC 
degranulation was evident in acute stage without 
any increase in number, yet the chronic stage was 
characterized with an increase in the number of 
MCs especially at areas with severe lymphocytic 
infiltrates in the papillary dermis.46Theses MCs 
were found to produce growth factors and 
angiogenic factors that induce skin thickening and 
fibrosis.47 
 
Mast cells and anaphylaxis 
Although anaphylaxis is considered a systemic 
event, the presence and activation of mast cells in 
specific organs may play a critical role in the 
severity. Within the heart, mast cells are located 
between myocardial fibers, around blood vessels 
and in the arterial intima. Activation of these 
critically positioned mast cells may directly 
contribute to cardiopulmonary failure. Cardiac mast 
cells in vitro release many of the classic mast cell 
mediators of anaphylaxis including PAF.48,49 PAF is 
thought to be a critical factor in the development of 
anaphylactic shock through its ability to induce 
hypotension and cardiac dysfunction .50 PAF-
induced anaphylactic shock in mice appears directly 
dependent on phosphoinositide-3 kinase (PI3K) and 
endothelial nitric oxide synthase (eNOS)-derived 
nitric oxide (NO) which functions as a potent 
vasodilator.51 
The overall number of mast cells may also be 
relevant in anaphylaxis. It is known that individuals 
with recurrent anaphylaxis tend to have more 
dermal mast cells than those without anaphylaxis. 
Mastocytosis, a disease characterized by the 
pathologic accumulation of mast cells in tissues, is 
often associated with spontaneous episodes of 
hypotension and has served as a unique disease 
model. Activating mutations in the tyrosine kinase 
Kit, such as D816V, are strongly associated with 
mastocytosis.52 Identification of this mutation 
suggests that additional yet unidentified genetic 
polymorphisms or mutations may potentially 
account for an increase in mast cell numbers, which 
may predispose individuals to recurrent 
anaphylaxis.53 
 
Novel directed treatment to the mast cell 
Mast cell therapeutics may be broadly classified 
into those directed at cell membrane targets 
(membrane receptors), to intracellular targets (cell 
signaling, gene expression) or to extracellular 
targets (released mediators); Table 1. Often 
treatment selection is tailored to include one or 
more of these agents depending on the individual 
patient and the specific allergic disease. Some are in 
clinical use as mast cell stabilizers, corticosteroids, 
omalizumab and antihistamines. 53  
As previously shown, MCs rely critically on 
TLR binding for activation in both allergic 
sensitization and exacerbations of allergic disease 
as well as in initiation of innate and adaptive 
immune responses. One possible future treatment 
for allergic diseases may be antibodies that act as 
decoys and bind LPS and PGN thereby preventing 
them from binding to TLR4 and TLR2 on the MC 
surface. Although this may effectively prevent the 
induction of Th2 responses to allergens encountered 
in the presence of LPS or PGN, this strategy is 
unlikely to affect innate and adaptive immune 
responses to pathogens because pathogens are 
recognized via multiple mechanisms and receptors 
on MCs and other cell types.54 
Another treatment strategy for allergic diseases 
is inhibition of the mediators released by MCs. One 
novel treatment incorporating this concept is the 
ongoing clinical investigations of TNFα blockade to 
treat severe refractory asthma. Several clinical trials 
have investigated the efficacy of different TNFα 
inhibitors in severe and moderate asthma with 
varying results. In an initial open label investigation 
of the TNFα blocker, etanercept, for treatment of 
severe asthma, improvement in metacholine airway 
hyperresponsiveness as well as improvement in 
lung functions and asthma symptoms was 
found.54,55 A randomized, double blind placebo 
controlled trial of etanercept in patients with severe 
asthma showed a small but significant improvement 
in asthma control55. However another clinical trial 
of a human monoclonal antibody against TNFα, 
golimumab, showed no clinical benefit.56 
There are many clinical trials in progress 
assessing the safety and efficacy of different IL4 
and IL13 inhibitors in the treatment of asthma and 
allergic rhinitis. These include studies of a 
Mast cell and atopy. 
 59
monoclonal antibody against IL13, monoclonal 
antibody inhibitors of the IL4 and IL13 receptors, 
and a recombinant human IL4 variant which 
inhibits IL4 and IL13 receptors.57 One preclinical 
study of an anti- IL13 antibody in allergic 
macaques showed decreases in allergic 
inflammation upon allergen exposure but had no 
effect on lung function.58 The human clinical trials 
of these agents for therapy of asthma and allergic 
rhinitis are ongoing.14 
As our understanding of mast cell signaling has 
evolved, potential new intracellular targets have 
been identified. A Syk tyrosine kinase inhibitor, 
R112, which disrupts mast cell IgE–FcεRI signaling 
has displayed promising results in some clinical 
trials and may represent a new class of allergy 
therapeutics.59,60 
CD63 is a tetraspanin present on the surface of 
mast cells that interacts with b1 integrins and 
modulates adhesion. Anti-CD63 monoclonal 
antibodies have shown the ability to decrease 
FcεRI-induced degranulation via impairment of the 









class Mechanism of action 
Stage of 
development 
Chromones Potential disruption of calcium influx, chloride ion transport and exocyctic  
processes 
Clinical use 
Β2 antagonists Increase cytosolic cAMP levels through binding  of Β2receptors Clinical use 





Block chemotaxis and degranulation Clinical trials 
Ca2+ & K+ 
channel 
antagonists 





Monoclonal antibody to CD63 which interferes with cellular adhesion to β1 
integrins and blocks Fc€RI-induced degranulation via impairment of Gab2-
PI3K pathway 
Pre-clinical 
Glucocorticoids Regulate transcription of numerous inflammatory genes Clinical use 
Syk Kinase 
inhibitors 
Block IgE- Fc€RI mediated downstream  signaling (phosphorylation) Clinical trials 
MAPK inhibitors Block the phosphorylation of multiple intracellular proteins (including 
transcription factors) that are involved in cellular proliferation, differentiation, 
survival and chronic inflammation 
Clinical trials 
Intracellular 
PDE4 inhibitors Blocks hydrolysis of cAMP to 5’ AMP Clinical trials 
5-LO inhibitor Blocks the conversion of arachidonic acid to LTA4 which subsequently  




Block the protease activity of tryptase Pre-clinical 
CysLTR 1 
antagonists 
Block the binding to and effects of CysLT on target organs Clinical use 
H1-4 receptor 
antagonists 
Blocks the binding to and effect of histamine on target  cells H1, H2;clinical use, 
H3; clinical trials, 
H4; pre-clinical  
PAR-2 
antagonists 




DP and CRTH-2 
receptor 
antagonists 
Block the binding to and effects of PGD2 on target cells Pre-clinical 
MAPK, mitogen-activated protein kinases, PI3K; phosphoinositoide-3 kinase, PDE; phosphodiestrase, 5-LO; 5-lipooxygenase, PAR-2; 
proteinase activated receptor 2, CRTH-2; chemoattractant receptor homologue on T-helper 2 cells, DP, D prostanoid 




MCs are one of the frontier cells  in allergic 
diseases. They are involved in all steps of allergy. 
New treatment targeting these cells might help 
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